BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AxioMed Spine Corporation Receives CE Mark for Freedom Lumbar Disc


5/12/2009 7:12:29 AM

Bookmark and Share

GARFIELD HEIGHTS, Ohio--(BUSINESS WIRE)--AxioMed® Spine Corporation (www.axiomed.com) announces the receipt of CE Mark approval for its Freedom® Lumbar Disc, an elastomeric total spinal disc replacement device. The CE Mark approval was received from the notified body after review of the company’s multi-center European clinical study and its portfolio of biocompatibility and biomechanical testing. This data also supported AxioMed’s Investigational Device Exemption approval by the US Food and Drug Administration. The CE Mark clears AxioMed for the introduction of the Freedom® Lumbar Disc into the EU Market.

Patrick McBrayer, AxioMed’s President and CEO stated, “The Freedom® Lumbar Disc is the only elastomeric lumbar total disc replacement device to receive CE Mark approval based on a rigorous multi-center clinical study conducted in the European Union. We are particularly pleased to be able to provide surgeons in Europe with the Freedom technology that has been shown to provide patients pain relief, reduced disability and improved lifestyle, based on monitored outcomes and feedback. We are also active in our multi-center pivotal clinical study under an IDE for our Freedom® disc.”

Neal Defibaugh, AxioMed’s Vice President of Clinical and Regulatory Affairs, added, “Our European clinical study results, coupled with the extensive portfolio of biocompatibility and biomechanical testing, provided substantial information for our notified body to assess the Freedom® Lumbar Disc. This regulatory milestone and our US FDA Investigational Device Exemption approval demonstrate that the Freedom® Lumbar Disc’s preclinical and clinical results can withstand rigorous regulatory review.”

The Freedom® Lumbar Disc is a viscoelastic one-piece, next generation total disc replacement featuring a polymer core, designed with the goal of restoring function of the spine and reducing pain and disability. CE Mark approval allows for the commercial distribution of the Freedom® Lumbar Disc throughout the European Union. AxioMed’s pivotal study, a multi-center US and EU evaluation of the Freedom® Lumbar Disc in skeletally mature patients with single-level degenerative disc disease, is designed with efficacy, safety and economic endpoints. AxioMed is also developing a cervical total disc replacement which will follow a similar regulatory pathway.

About AxioMed Spine Corporation

AxioMed’s mission is to develop products focused on spinal function for patients with degenerative spine disease, thus advancing the standard of care beyond fusion and first generation discs. The Freedom Lumbar Disc was developed and designed by a team of clinicians and experts in the fields of biomechanics, pathology, spinal surgery and polymer science. Focusing on restoration of the natural function of the spine, AxioMed will enhance human health through research, innovation, development and service world-wide. For more information about AxioMed, please visit our web site at www.axiomed.com.

Contact:

AxioMed Spine Corporation Gerald Baty, 216-587-5566 Chief Financial Officer Facsimile: 216-587-3388 Jbaty@axiomed.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES